|Systematic (IUPAC) name|
|Mol. mass||217.35 g/mol|
Prolintane (Catovit) is a stimulant of norepinephrine-dopamine reuptake inhibitors developed in the 1950s which is closely related in chemical structure to other drugs such as pyrovalerone, MDPV, and propylhexedrine and with a similar mechanism of action. It is a mild stimulant with a very good safety profile. The good safety profile of this drug makes it suitable for use in elderly people to increase motivation and counteract the effects of senile dementia and age-related cognitive decline. However the drug has now been banned in European countries. Prolintane is a nootropic with a better safety profile than propylhexedrine, cyclopentamine and caffeine. Many cases of prolintane abuse have been reported.
- α-PVP (β-ketone-prolintane. Prolintanone.)
- Prolintanol (β-hydroxyl-prolintane. Prolintanol.)
- Methylenedioxypyrovalerone (MDPV)
- Pyrovalerone (Centroton, Thymergix)
- Hollister, L. E.; Gillespie, H. K. (1970). "A new stimulant, prolintane hydrochloride, compared with dextroamphetamine in fatigued volunteers". The Journal of Clinical Pharmacology 10 (2): 103–109.
- GB Patent 807835
- Nicholson, A. N.; Stone, B. M.; Jones, M. M. (1980). "Wakefullness and reduced rapid eye movement sleep: Studies with prolintane and pemoline". British Journal of Clinical Pharmacology 10 (5): 465–472.
- Kuitunen, T.; Kärkkäinen, S.; Ylitalo, P. (1984). "Comparison of the acute physical and mental effects of ephedrine, fenfluramine, phentermine and prolintane". Methods and Findings in Experimental and Clinical Pharmacology 6 (5): 265–270.